Citations

Clear

16281 citation(s) found for "Yu, David".

MINT Registry: Rationale and Study Design
Limaye, Kaustubh , Dolia, Jaydevsinh , Ezzeldin, Mohamad , Duarte, Daniel Vela, Doss, Vinodh T , Spiotta, Alejandro M , Asi, Khaled, Yavagal, Dileep, Jones, Jesse , Tanweer, Omar , Brinjikji, Waleed , Limaye, Kaustubh , Dolia, Jaidevsinh , Kasab, Sami Al , Vela‐Duarte, Daniel , Lahoti, Sourabh A. , Hasan, David , Saini, Vasu A , Mehta, Tapan , Hassan, Ameer E , Haussen, Diogo C

Mayo Clinic

Stroke: Vascular and Interventional Neurology | July 7, 2024 | Volume: 4 | Issue: 5 | Pages: No page available

10.1161/svin.124.001384 | PMID 41586276 Get It

Background Mechanical thrombectomy has become the standard of care for treatment of acute ischemic stroke secondary to large‐vessel occlusion up to 24 hours from last known normal time. Multiple different techniques for mechanical thrombectomy have been described, including a direct aspiration first‐pass technique and stent retriever thrombectomy. With a direct aspiration first‐pass technique, classically, a large‐bore aspiration catheter is delivered over a microcatheter and microwire to the clot. Recently, a novel macrowire has been introduced as a potential alternative to the use of microwire–microcatheter to allow the delivery of the aspiration catheter. The aim of this study is to develop a multicenter registry comparing delivery of an aspiration catheter for intracranial thrombectomy for acute ischemic stroke secondary to emergent large‐vessel occlusion over a macrowire in comparison with traditional use of microcatheter and microwire. Methods MINT (Macrowire for Intracranial Thrombectomy) is a multicenter, observational study currently enrolling patients with large‐vessel occlusion who underwent mechanical thrombectomy using a macrowire to deliver the aspiration catheter to the intracranial occlusion. All the participating sites will screen and report cases on a monthly basis. The decision to use the macrowire and various aspiration catheters is at the discretion of the interventionalist. Results We will collect patient's clinical, demographic, and radiographic data. In addition, we plan to collect procedure variables and postprocedure clinical and imaging data. Outcomes include successful delivery of the reperfusion catheter to the clot interface, time taken from groin access to first pass, and a bailout strategy for thrombectomy in cases where this is not feasible. Conclusion The MINT registry will add to our understanding of safety and efficacy of this novel macrowire in intracranial thrombectomy. This registry will also highlight and allow for understanding in workflow improvements from simplifying setup and possibly cost effectiveness of this technique.
Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.
Sobrero, Alberto , García‐Alfonso, Pilar , Höchster, Howard S. , Qin, Shukui , Schelman, William R., Fan, Songhua, Yu, Ziji, Chen, Lucy F., Bekaii‐Saab, Tanios , Dasari, Arvind , Eng, Cathy , Lonardi, Sara , Yoshino, Takayuki , Yao, James C. , Bianchi, Andrea Sartore , Hubbard, Joleen M. , Price, Timothy Jay , Tougeron, David , Li, Jin , Tabernero, Josep

Mayo Clinic

Journal of Clinical Oncology | July 5, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3579-3579

10.1200/jco.2024.42.16_suppl.3579 Get It

3579 Background: Fruquintinib (F) is a highly selective, oral tyrosine kinase inhibitor of all 3 VEGF receptors. Based on FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) data, F was approved by the US FDA for previously treatedmetastatic colorectal cancer (mCRC). Efficacy and safety of F + best supportive care (BSC) vs placebo (P) + BSC were analyzed according to prior treatment (tx) sequence using FRESCO and FRESCO-2 data. Methods: In FRESCO and FRESCO-2, patients (pts) were randomized 2:1 to receive F 5 mg or matching P, PO daily x 21 days every 28 days. In FRESCO, eligible pts had received ≥2 prior chemotherapy regimens and were permitted to have received prior anti-VEGF and/or anti-EGFR therapies, whereas in FRESCO-2, in addition to standard chemotherapies, anti-VEGF, and anti-EGFR therapies if indicated, prior exposure to trifluridine/tipiracil (TAS) and/or regorafenib (rego) was required. FRESCO-2 pts must have also received a BRAF inhibitor and/or immunotherapy, if indicated and available in their country. Results: In FRESCO (F n=278 vs P n=138), no pts had received rego and 16/416 pts (4%) had received TAS. InFRESCO-2, prior therapies were balanced between F vs P arms; pts had received prior TAS or rego in these sequences: prior TAS only (n=240 vs n=121); prior rego only (n=40 vs n=18); prior rego then TAS (n=84 vs n=45); prior TAS then rego (n=95 vs n=44). Improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS (HRs 0.53–0.77) and PFS (HRs 0.25–0.37). F safety profile was consistent regardless of prior tx sequence (Table). Conclusions: F is effective in mCRC with a manageable safety profile regardless of prior TAS or rego tx and sequence. Improvement with F was similar for OS and PFS despite the number and sequence of prior regimens. F provides a new tx option for pts with previously treated mCRC regardless of prior TAS or rego exposure. Clinical trial information: NCT04322539 . [Table: see text]
Features of Importance in Nasal Endoscopy: Deriving a Meaningful Framework
Babahaji, Layla M., Ganeshan, Vinayak , Nguyen, Thinh S., Ahmed, Omar G. , Barton, Blair M. , Halawi, Akaber, Joe, Stephanie, Marino, Michael J. , Patel, Zara M. , Rangarajan, Sanjeet V., Riley, Charles A. , Roxbury, Christopher R. , Tabaee, Abtin, Tang, Dennis M. , Wu, Arthur W. , Yim, Michael , Bidwell, Jonathan, Riley, Charles A. , McCoul, Edward D , Patel, Zara , Wu, Arthur W , Chandra, Rakesh Kumar , Chen, Philip G. , Gudis, David A. , Higgins, Thomas S , Kuan, Edward C , Ramakrishnan, Vijay R , McCoul, Edward D.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | July 5, 2024 | Volume: 171 | Issue: 4 | Pages: 1052-1061

10.1002/ohn.889 | PMID 38967295 Get It

AbstractObjectiveCritical components of the nasal endoscopic examination have not been definitively established for either the normal examination or for clinical disorders. This study aimed to identify concordance among rhinologists regarding the importance of examination findings for various nasal pathologies.Study DesignA consortium of 19 expert rhinologists across the United States was asked to rank the importance of findings on nasal endoscopy for 5 different sinonasal symptom presentations.SettingAn online questionnaire was distributed in July 2023.MethodsThe questionnaire utilized JotForm® software and featured 5 cases with a set of 4 identical questions per case, each covering a common indication for nasal endoscopy. Rankings were synthesized into Normalized Attention Scores (NASs) and Weighted Normalized Attention Scores (W‐NASs) to represent the perceived importance of each feature, scaled from 0 to 1.ResultsGeneral concordance was found for examination findings on nasal endoscopy within each case. The perceived features of importance differed between cases based on clinical presentation. For instance, in evaluating postnasal drip, the middle meatus was selected as the most important structure to examine (NAS, 0.73), with mucus selected as the most important abnormal finding (W‐NAS, 0.66). The primary feature of interest for mucus was whether it was purulent or not (W‐NAS, 0.67). Similar analyses were performed for features in each case.ConclusionThe implicit framework existing among rhinologists may help standardize examinations and improve diagnostic accuracy, augment the instruction of trainees, and inform the development of artificially intelligent algorithms to enhance clinical decision‐making during nasal endoscopy.
Sex and gender differences in cognitive resilience to aging and Alzheimer's disease
Boyle, Rory , Casaletto, Kaitlin B. , Vila‐Castelar, Clara , Colverson, Aaron , Palpatzis, Eleni , Eissman, Jaclyn M. , Ng, Ted Kheng Siang , Raghavan, Sheelakumari, Akinci, Müge , Vonk, Jet M. J. , Machado, Luiza Santos , Zanwar, Preeti , Shrestha, Hom Lal , Wagner, Maude , Sohrabi, Hamid R. , Okonkwo, Ozioma C. , Hohman, Timothy J. , Ewers, Michael , Group, for the Reserve, Resilience and Protective Factors Professional Interest Area, Sex and Gender Professional Interest area and the ADDRESS! Special Interest, Seto, Mabel , Arenaza‐Urquijo, Eider M. , Anstey, Kaarin Jane , Raghavan, Sheelakumari , Tamburin, Stefano , Loi, Samantha M. , Bartrés‐Faz, David , Dubal, Dena B. , Vemuri, Prashanthi , Buckley, Rachel F. , Group, for the Reserve, Resilience and Protective Factors Professional Interest Area, Sex and Gender Professional Interest area and the ADDRESS! Special Interest

Mayo Clinic

Alzheimer's & Dementia | July 5, 2024 | Volume: 20 | Issue: 8 | Pages: 5695-5719

10.1002/alz.13844 | PMID 38967222 Get It

Abstract Sex and gender—biological and social constructs—significantly impact the prevalence of protective and risk factors, influencing the burden of Alzheimer's disease (AD; amyloid beta and tau) and other pathologies (e.g., cerebrovascular disease) which ultimately shape cognitive trajectories. Understanding the interplay of these factors is central to understanding resilience and resistance mechanisms explaining maintained cognitive function and reduced pathology accumulation in aging and AD. In this narrative review, the ADDRESS! Special Interest Group (Alzheimer's Association) adopted a multidisciplinary approach to provide the foundations and recommendations for future research into sex‐ and gender‐specific drivers of resilience, including a sex/gender‐oriented review of risk factors, genetics, AD and non‐AD pathologies, brain structure and function, and animal research. We urge the field to adopt a sex/gender‐aware approach to resilience to advance our understanding of the intricate interplay of biological and social determinants and consider sex/gender‐specific resilience throughout disease stages. Highlights Sex differences in resilience to cognitive decline vary by age and cognitive status. Initial evidence supports sex‐specific distinctions in brain pathology. Findings suggest sex differences in the impact of pathology on cognition. There is a sex‐specific change in resilience in the transition to clinical stages. Gender and sex factors warrant study: modifiable, immune, inflammatory, and vascular.
Predicting Provider Workload Using Predicted Patient Risk Score and Social Determinants of Health in Primary Care Setting
Huang, Yu-Li, Watral, Alexandra , Blocker, Renaldo C., Rushlow, David , Jiang, Yiqun , Jiang, Yiqun , Huang, Yu-Li

Mayo Clinic

Applied Clinical Informatics | July 3, 2024 | Volume: 15 | Issue: 03 | Pages: 511-527

10.1055/s-0044-1787647 | PMID 38960376 Get It

Abstract Background Provider burnout due to workload is a significant concern in primary care settings. Workload for primary care providers encompasses both scheduled visit care and non–visit care interactions. These interactions are highly influenced by patients' health conditions or acuity, which can be measured by the Adjusted Clinical Group (ACG) score. However, new patients typically have minimal health information beyond social determinants of health (SDOH) to determine ACG score. Objectives This study aims to assess new patient workload by first predicting the ACG score using SDOH, age, and gender and then using this information to estimate the number of appointments (scheduled visit care) and non–visit care interactions. Methods Two years of appointment data were collected for patients who had initial appointment requests in the first year and had the ACG score, appointment, and non–visit care counts in the subsequent year. State-of-art machine learning algorithms were employed to predict ACG scores and compared with current baseline estimation. Linear regression models were then used to predict appointments and non–visit care interactions, integrating demographic data, SDOH, and predicted ACG scores. Results The machine learning methods showed promising results in predicting ACG scores. Besides the decision tree, all other methods performed at least 9% better in accuracy than the baseline approach which had an accuracy of 78%. Incorporating SDOH and predicted ACG scores also significantly improved the prediction for both appointments and non–visit care interactions. The R 2 values increased by 95.2 and 93.8%, respectively. Furthermore, age, smoking tobacco, family history, gender, usage of injection birth control, and ACG were significant factors for determining appointments. SDOH factors such as tobacco usage, physical exercise, education level, and group activities were strongly correlated with non–visit care interactions. Conclusion The study highlights the importance of SDOH and predicted ACG scores in predicting provider workload in primary care settings.
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).
Moroney, John W. , Alvarez, Edwin , Lin, Yvonne G. , DiLallo, Gillian, Mahdi, Haider , Mandrekar, Sumithra J. , Matulonis, Ursula A. , Cantillo, Evelyn , Zemla, Tyler , Shah, Jigna, Liu, Joyce F. , Secord, Angeles Alvarez , Nixon, Andrew B. , Kozono, David , Slomovitz, Brian M.

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS5642-TPS5642

10.1200/jco.2024.42.16_suppl.tps5642 Get It

TPS5642 Background: The landscape in the management of recurrent or persistent endometrial cancer (EC) continues to evolve. Anti-PD-1/PD-L1 immune checkpoint inhibitors (ICI) as monotherapy or when combined with the VEGF-targeted tyrosine kinase inhibitor, lenvatinib, have demonstrated promising response rates in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) and MS-stable (MSS)/MMR-proficient (MMRp) EC, respectively. Recent studies have also shown a benefit with adding ICI to standard of care chemotherapy in the frontline setting. Pts with MSI-H/dMMR tumors seem to derive the greatest benefit. Approximately, 30% of recurrent EC pts fall into this category. Pairing ICI with targeted therapies carries the potential to elicit prolonged anti-tumor effects. Atezolizumab (Atezo) is a humanized monoclonal PD-L1 inhibitor that has demonstrated monotherapy antitumor activity in relapsed recurrent EC, and other solid tumors (e.g. NSCLC, HCC) as monotherapy and as part of combinatorial therapy. The AFT-50/EndoMAP study is a phase IB/II non-randomized, multicenter, 2-arm, multi-cohort platform trial designed to evaluate the efficacy and safety of biomarker-driven combination regimens, both with Atezo (AFT-50A) and without Atezo (AFT-50B) with biomarker-defined targeted agents in pts with recurrent or persistent EC. Methods: Eligible pts have recurrent or persistent EC with no more than 2 prior lines of therapy. FoundationOne CDx (F1CDx) NGS assay will be used for genomic tumor profiling. In AFT-50A, pts may be eligible for one of the following doublets: Atezo+talazoparib (tumors with genomic loss of heterozygosity (gLOH ≥16%), Atezo+Trastuzumab emtansine (ERBB2/HER2 mutated or amplified tumors), and Atezo+Tiragolumab (MSI-H and/or TMB-H). The Atezo+bevacizumab (biomarker unmatched) and Atezo+ipatasertib (PIK3CA/PTEN/AKT1-altered tumors) cohorts have completed accrual. Each cohort will enroll ~20 pts with potential adjustment to account for statistical and clinical considerations. AFT-50A pts will receive Atezo in addition to a targeted agent (per study-approved dosing schedule) until progression, unacceptable toxicity, pt withdrawal, death, or study termination. AFT-50B pts will be eligible for inavolisib (PIK3CAm/PTEN and AKT1wt-altered tumors) + letrozole or giredestrant + abemaciclib (RB1wt, estrogen receptor positive tumors). The primary endpoint for AFT-50A is confirmed overall response rate (ORR) for each arm, and for AFT-50B is 6-month progression free survival. Secondary endpoints include disease control rate, duration of response, OS, safety and tolerability. As a platform study, additional arms may be added, as supported by evolving understanding of EC and molecular targets. EndoMAP is actively enrolling at 20 sites in the US with a target of 25 sites nationwide. Clinical trial information: NCT04486352 .
SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC).
Moseley, Anna , Chiorean, E. Gabriela , Gay, Carl M. , Byers, Lauren A. , Wistuba, Ignacio I. , Mahdi, Haider , Starr, Jason S. , Chae, Young Kwang , Zhen, David B. , Burgess, Earle F. , Swisher, Elizabeth M. , Othus, Megan , Kurzrock, Razelle

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4201-TPS4201

10.1200/jco.2024.42.16_suppl.tps4201 Get It

TPS4201 Background: Poorly differentiated, extrapulmonary NEC are rare cancers with median overall survival (OS) <1 year. Treatment is extrapolated from small cell lung cancer (SCLC) with use of P (cisplatin or carboplatin) + E. More effective treatment regimens and predictive biomarkers are needed to improve outcomes. In SCLC, induction therapy with combination of P/E + PD-L1 checkpoint inhibitor atezolizumab and maintenance atezolizumab improved OS (12.3 months vs 10.3 months; HR 0.70, 95% CI 0.54 – 0.91, P=0.007) vs P/E alone (1). No study to date has compared PD-1/PD-L1 inhibition during induction only vs during induction and maintenance therapy. In SCLC, distinct molecular subtypes can be identified by the presence of specific transcription factors (e.g., ASCL1, NEUROD1, POU2F3) or an inflamed gene signature (SCLC-I), with SCLC-I pts more likely to benefit clinically from the addition of immunotherapy (2). In this study we plan to test the benefit of adding atezolizumab to induction P/E as well as the role of adding maintenance atezolizumab after induction P/E plus atezolizumab. We also plan to correlate tumor- and blood-based subtype biomarkers with response to therapy. Methods: Eligible pts ≥18 years old have evaluable, histologically confirmed extrapulmonary NEC, Zubrod PS ≤2, and are allowed to have up to 1 cycle of P/E prior to enrollment. P (cisplatin 75 mg/m2 or carboplatin AUC 5, iv) on day 1, E 100 mg/m2 iv on days 1-3, and atezolizumab 1200 mg iv on day 1 of q21 day cycles. Pts are randomized to 1 of 3 arms: A) Induction P/E + atezolizumab -> maintenance atezolizumab B) Induction P/E + atezolizumab -> observation C) Induction P/E -> observation. The primary objective is to compare the overall survival (OS, from randomization) between arms in a fixed sequence: A vs C -> B vs C -> A vs B. Secondary objectives include comparing OS (from start of maintenance/observation), progression free survival, response rate, duration of response, and safety/tolerability across arms. Tumor and blood samples will be banked for future biomarker analyses, including immunohistochemistry of transcription factors on tissue and whole exome sequencing on tumor and circulating tumor DNA. With 189 pts (168 eligible), the study has 84% power to detect an improvement in 12-months OS from 35% to 57.5% (HR 0.53). This study was activated December 2021 with 3 pts enrolled over 1 year due to restricting enrollment of NEC of small cell histology only. The protocol was amended in January 2023 to broaden eligibility to all NEC subtypes (small cell, large cell, and undefined histology with Ki-67 ≥55%). As of January 2024, 35 patients have been enrolled. A protocol amendment is planned to remove the need for Ki-67 index for NEC of genitourinary origin to improve accrual. 1. Horn L, et al. N Engl J Med 2018. 2. Gay CM, et al. Cancer Cell 2021. Clinical trial information: NCT05058651 .
Effectiveness and safety of irreversible electroporation when used for the ablation of stage 3 pancreatic adenocarcinoma: A registry study (DIRECT).
Martin, Robert C.G. , Bilimoria, Malcolm M., Heithaus, Robert Evans , Kruse, Edward, Desai, Darius C., Narayanan, Govindarajan, Chan, Carlos H.F. , Kluger, Michael D. , Iannitti, David A. , Cleary, Sean P. , Polanco, Patricio Marcelo , Hammill, Chet W. , Velanovich, Vic , White, Rebekah R.

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e16301-e16301

10.1200/jco.2024.42.16_suppl.e16301 Get It

e16301 Background: Outcomes for patients with Stage 3 pancreatic ductal adenocarcinoma (PDAC) remain poor with a mean overall survival (OS) of 11 months. Irreversible electroporation (IRE) is a method of local tumor ablation that causes cell death by disrupting homeostasis in the cell membrane. Previous research suggests IRE can be useful in the multi-disciplinary treatment of Stage 3 PDAC. The present study was designed to assess the effectiveness and safety of IRE for Stage 3 PDAC in a real-world setting after induction chemotherapy. Methods: Patients with Stage 3 PDAC treated with IRE were prospectively enrolled in a multicenter registry study. Enrollment required 3 months of active multi-agent chemotherapy, with no progression before IRE treatment. Endpoints were 30- and 90-day mortality from enrollment and the new onset of an adverse event (AE). Results: 87 patients were enrolled in the registry between May 2019 and May 2023. Mean age was 64.0 ± 8.4 years, 57.5% were female and mean tumor diameter was 2.2 ± 0.7 cm. Mean time from diagnosis to IRE treatment was 8.9 ± 4.9 months. All subjects underwent induction chemotherapy with the most common being FOLFIRINOX alone, gemcitabine with albumin-bound paclitaxel, or a combination of both in 47 (54.0%) patients. Thirty-seven (42.5%) patients had prior radiation therapy. All procedures were performed using an open approach with 50 (57.5%) for in-situ tumor ablation and 37 (42.5%) with the intent of margin accentuation in combination with resection. Major adjunctive procedures were performed for 70 (80.5%) patients. Common adjunctive surgeries were cholecystectomy (33.3%), Whipple procedure (28.7%) and either distal or subtotal pancreatectomy (11.4%). Mean IRE delivery time was 55.7 ± 54.5 minutes with an average of 3.1 probes (range 2 to 6) used per procedure. There was a mean of 1031.1 ± 882.1 pulses delivered per procedure. The 30- and 90-day mortality was 3/87 (3.4%) and 4/82 (4.9%) respectively. There were 21 (24.1%) patients who developed AEs related to IRE treatment during the 90-day post-procedure period (9 patients had AEs that were definitely related to IRE, 5 probably and 7 possibly). Of these related events, only three were Grade 4 or higher (arterial hemorrhage, cardiac arrest, and septic shock). Overall, gastrointestinal related AEs were the most common representing 16 of the 28 (57.1%) of all AEs associated with the IRE procedure. One patient died within 30 days of the procedure due to an intraperitoneal arterial hemorrhage that was deemed to be definitely related to the IRE treatment. Conclusions: The use of IRE for curative intent tumor ablation alone or in combination with resection following induction chemotherapy in patients with locally advanced Stage 3 PDAC has acceptable safety and is associated with acceptable morbidity and mortality rates in appropriately selected patients. Clinical trial information: NCT03899649 .
Cancer Survivorship Care in the United States at Facilities Accredited by the Commission on Cancer
Mullett, Timothy W. , Francescatti, Amanda B. , Funk, Elizabeth, Nelson, Heidi , Freyer, David R. , Stal, Julia , Miller, Kimberly Ann , Boughey, Judy C. , Funk, Elizabeth

Mayo Clinic

JAMA Network Open | July 3, 2024 | Volume: 7 | Issue: 7 | Pages: e2418736

10.1001/jamanetworkopen.2024.18736 | PMID 38958979 Get It

ImportanceSince 2021, American College of Surgeons Commission on Cancer (CoC) accreditation standards require providing a survivorship program for patients with adult-onset cancer treated with curative intent. Since more than 70% of all patients with cancer in the US are treated at CoC-accredited facilities, this presents an opportunity for a landscape analysis of survivorship care availability.ObjectiveTo determine the prevalence, types, and outcomes of cancer survivorship services at CoC-accredited facilities.Design, Setting, and ParticipantsThis survey study used an anonymous, online, cross-sectional survey conducted from May 4 to 25, 2023. Participants were CoC-accredited facilities in the US representing diverse CoC program categories, institutional characteristics, geographic regions, and practice types. Department of Veterans Affairs cancer programs were excluded due to data usage restrictions. Data were analyzed from July to October 2023.ExposureCoC Survivorship Standard 4.8 was released in October 2019 and programs were expected to adhere to the Standard beginning January 1, 2021.Main Outcomes and MeasuresQuestions included self-reported survivorship program characteristics, availability of services aligned to CoC Survivorship Standard 4.8, and perceived program impacts. Response frequencies and proportions were determined in aggregate and by CoC program category.ResultsThere were 1400 eligible programs, and 384 programs participated (27.4% response rate). All regions and eligible program categories were represented, and most had analytic caseloads of 500 to 4999 patients in 2021. Most survivorship program personnel included nurses (334 programs [87.0%]) and social workers (278 programs [72.4%]), while physical (180 programs [46.9%]) and occupational (87 programs [22.7%]) therapists were less common. Services most endorsed as available for all survivors were screening for new cancers (330 programs [87.5%]), nutritional counseling (325 programs [85.3%]), and referrals to specialists (320 programs [84.7%]), while treatment summaries (242 programs [64.7%]), and survivorship care plans (173 programs [43.0%]), sexual health (217 programs [57.3%]), and fertility (214 programs [56.9%]) were less common. Survivorship services were usually delivered by cancer treatment teams (243 programs [63.3%]) rather than specialized survivorship clinics (120 programs [31.3%]). For resources needed, additional advanced practice clinicians with dedicated survivorship effort (205 programs [53.4%]) and electronic health record enhancements (185 programs [48.2%]) were most endorsed. Lack of referrals and low patient awareness were endorsed as the primary barriers. A total of 335 programs (87.2%) agreed that Survivorship Standard 4.8 helped advance their programs.Conclusions and RelevanceThese findings of this survey study of CoC-accredited programs establish a benchmark for survivorship care delivery in the US, identify gaps in specific services and opportunities for intervention, contribute to longitudinal reevaluation for tracking progress nationally, and suggest the value of survivorship care standards.
Signal detrending in elastographic wave data with large motion artifacts through a 2D Whittaker smoother
David, Rosen P., Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

The Journal of the Acoustical Society of America | July 3, 2024 | Volume: 155 | Issue: 3_Supplement | Pages: A246-A246

10.1121/10.0027381 Get It

A variety of advanced shear wave elastography techniques require the measurement of frequency-resolved phase velocity to properly characterize wave signals where factors such as tissue viscosity or guided wave effects are present. However, when applying these techniques in a dynamic environment where extrinsic motion cannot be limited, nonlinear and nonstationary trends can be expected in the motion signal used for phase velocity estimation. Because such extrinsic motion signals can contaminate a broad range of frequencies, they can produce significant errors in the phase velocity estimates. In this study, we propose a spatiotemporal detrending approach for elastography wave motion signals built from a 2D Whittaker smoother. This smoother has its origins in nonparametric regression and is well suited for fitting nonlinear curves of arbitrary shape. The resulting detrending filter was applied to Lamb wave signals from clinical ultrasound bladder vibrometry measurements. We found that the proposed detrending filter allowed for phase velocity estimates to be made in acquisitions that are otherwise be too corrupted by large motion. This works was supported by a grant from the NIH (DK131685)